Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice

1Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends-An Update. Cancer Epidemiol Biomarkers Prev 2016; 25: 16-27. doi: 10.1158/1055-9965.EPI-15-0578Torre LA Siegel RL Ward EM Jemal A Global Cancer Incidence and Mortality Rates and Trends-An Update Cancer Epidemiol Biomarkers Prev 2016 25 16 27 10.1158/1055-9965.EPI-15-0578Open DOISearch in Google Scholar

2Oing C, Rink M, Oechsle K, Seidel C, von Amsberg G, Bokemeyer C. Second line chemotherapy for advanced and metastatic urothelial carcinoma: vinflunine and beyond – a comprehensive review of the current literature. J Urol 2016; 195: 254-63. doi: 10.1016/j.juro.2015.06.115Oing C Rink M Oechsle K Seidel C von Amsberg G Bokemeyer C Second line chemotherapy for advanced and metastatic urothelial carcinoma: vinflunine and beyond – a comprehensive review of the current literature J Urol 2016 195 254 63 10.1016/j.juro.2015.06.115Open DOISearch in Google Scholar

3Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J Clin Oncol 2011; 29: 2432-8. doi: 10.1200/JCO.2011.34.8433Galsky MD Hahn NM Rosenberg J Sonpavde G Hutson T Oh WK et al Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy J Clin Oncol 2011 29 2432 8 10.1200/JCO.2011.34.8433Open DOISearch in Google Scholar

4Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27: 4454-61. doi: 10.1200/JCO.2008.20.5534Bellmunt J Théodore C Demkov T Komyakov B Sengelov L Daugaard G et al Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract J Clin Oncol 2009 27 4454 61 10.1200/JCO.2008.20.5534Open DOISearch in Google Scholar

5Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong Y-N, Kumar Pal S, et al. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Ann Oncol 2018; 29: 361-9. doi: 10.1093/annonc/mdx692Bamias A Tzannis K Harshman LC Crabb SJ Wong Y-N Kumar Pal S et al Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) Ann Oncol 2018 29 361 9 10.1093/annonc/mdx692Open DOISearch in Google Scholar

6Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol 2017; 35: 2117-24. doi: 10.1200/JCO.2016.71.6795Apolo AB Infante JR Balmanoukian A Patel MR Wang D Kelly K et al Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study J Clin Oncol 2017 35 2117 24 10.1200/JCO.2016.71.6795Open DOISearch in Google Scholar

7Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 2016; 34: 3119-25. doi: 10.1200/JCO.2016.67.9761Massard C Gordon MS Sharma S Rafii S Wainberg ZA Luke J et al Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer J Clin Oncol 2016 34 3119 25 10.1200/JCO.2016.67.9761Open DOISearch in Google Scholar

8Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multi-centre, open-label, phase 3 randomised controlled trial. Lancet 2018; 391: 748-57. doi: 10.1016/S0140-6736(17)33297-XPowles T Durán I van der Heijden MS Loriot Y Vogelzang NJ De Giorgi U et al Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multi-centre, open-label, phase 3 randomised controlled trial Lancet 2018 391 748 57 10.1016/S0140-6736(17)33297-XOpen DOISearch in Google Scholar

9Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017; 18: 312-22. doi: 10.1016/S1470-2045(17)30065-7Sharma P Retz M Siefker-Radtke A Baron A Necchi A Bedke J et al Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial Lancet Oncol 2017 18 312 22 10.1016/S1470-2045(17)30065-7Open DOISearch in Google Scholar

10Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017; 389: 67-76. doi: 10.1016/S0140-6736(16)32455-2Balar AV Galsky MD Rosenberg JE Powles T Petrylak DP Bellmunt J et al Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial Lancet 2017 389 67 76 10.1016/S0140-6736(16)32455-2Open DOISearch in Google Scholar

11Balar A V, Castellano D, O’Donnell PH, Grivas P, Vuky J, Powles T, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017; 18: 1483-92. doi: 10.1016/S1470-2045(17)30616-2Balar A V Castellano D O’Donnell PH Grivas P Vuky J Powles T et al First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study Lancet Oncol 2017 18 1483 92 10.1016/S1470-2045(17)30616-2Open DOISearch in Google Scholar

12Galsky MD, Arija JÁA, Bamias A, Davis ID, De Santis M, Kikuchi E, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2020; 395: 1547-57. doi: 10.1016/S0140-6736(20)30230-0Galsky MD Arija JÁA Bamias A Davis ID De Santis M Kikuchi E et al Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial Lancet 2020 395 1547 57 10.1016/S0140-6736(20)30230-0Open DOISearch in Google Scholar

13Bellmunt J, Choueiri TK, Fougeray R, Schutz FAB, Salhi Y, Winquist E, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010; 28: 1850-5. doi: 10.1200/JCO.2009.25.4599Bellmunt J Choueiri TK Fougeray R Schutz FAB Salhi Y Winquist E et al Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens J Clin Oncol 2010 28 1850 5 10.1200/JCO.2009.25.4599Open DOISearch in Google Scholar

14Matsumoto R, Abe T, Ishizaki J, Kikuchi H, Harabayashi T, Minami K, et al. Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan. Jpn J Clin Oncol 2018; 48: 771-6. doi: 10.1093/jjco/hyy094Matsumoto R Abe T Ishizaki J Kikuchi H Harabayashi T Minami K et al Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan Jpn J Clin Oncol 2018 48 771 6 10.1093/jjco/hyy094Open DOISearch in Google Scholar

15Ding X, Chen Q, Yang Z, Li J, Zhan H, Lu N, et al. Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis. Cancer Manag Res 2019; 11: 4171-84. doi: 10.2147/CMAR.S176937Ding X Chen Q Yang Z Li J Zhan H Lu N et al Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis Cancer Manag Res 2019 11 4171 84 10.2147/CMAR.S176937Open DOISearch in Google Scholar

16Rouanne M, Radulescu C, Adam J, Allory Y. PD-L1 testing in urothelial bladder cancer: essentials of clinical practice. World J Urol 2020; [Ahead of print]. doi: 10.1007/s00345-020-03498-0Rouanne M Radulescu C Adam J Allory Y PD-L1 testing in urothelial bladder cancer: essentials of clinical practice World J Urol 2020 [Ahead of print] 10.1007/s00345-020-03498-0Open DOISearch in Google Scholar

17Rosenberg JE, Hoffman-Censits J, Powles T, Van Der Heijden MS, Balar A V., Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016; 387: 1909-20. doi: 10.1016/S0140-6736(16)00561-4Rosenberg JE Hoffman-Censits J Powles T Van Der Heijden MS Balar A V. Necchi A et al Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Lancet 2016 387 1909 20 10.1016/S0140-6736(16)00561-4Open DOISearch in Google Scholar

18Stewart TF, Petrylak DP. Atezolizumab in understudied populations with bladder cancer. Nat Rev Urol 2019; 16: 449-50. doi: 10.1038/s41585-019-0200-8Stewart TF Petrylak DP Atezolizumab in understudied populations with bladder cancer Nat Rev Urol 2019 16 449 50 10.1038/s41585-019-0200-8Open DOISearch in Google Scholar

19Sternberg CN, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, et al. Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract. Eur Urol 2019; 76: 73-81. doi: 10.1016/j.eururo.2019.03.015Sternberg CN Loriot Y James N Choy E Castellano D Lopez-Rios F et al Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract Eur Urol 2019 76 73 81 10.1016/j.eururo.2019.03.015Open DOISearch in Google Scholar

20Flannery K, Boyd M, Black-Shinn J, Robert N, Kamat AM. Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study. Future Oncol 2019; 15: 1323-34. doi: 10.2217/fon-2018-0654Flannery K Boyd M Black-Shinn J Robert N Kamat AM Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study Future Oncol 2019 15 1323 34 10.2217/fon-2018-0654Open DOISearch in Google Scholar

21Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, et al. Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res 2017; 5: 417-24. doi: 10.1158/2326-6066.CIR-16-0325Tumeh PC Hellmann MD Hamid O Tsai KK Loo KL Gubens MA et al Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC Cancer Immunol Res 2017 5 417 24 10.1158/2326-6066.CIR-16-0325Open DOISearch in Google Scholar

22Rosenberg J, Petrylak D, Abidoye O, Van der Heijden MS, Hofman-Censits J, Necchi A, et al. 21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): results from a pivotal multicenter phase II study (IMvigor 210). Eur J Cancer 2015; 51(Suppl 3): S720. [abstract]. doi: 10.1016/s0959-8049(16)31942-6Rosenberg J Petrylak D Abidoye O Van der Heijden MS Hofman-Censits J Necchi A et al 21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): results from a pivotal multicenter phase II study (IMvigor 210) Eur J Cancer 2015 51Suppl 3 S720 {abstract] 10.1016/s0959-8049(16)31942-6Open DOISearch in Google Scholar

23Parikh RB, Galsky MD, Gyawali B, Riaz F, Kaufmann TL, Cohen AB, et al. Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma at the end of life: insights from real-world practice. Oncologist 2019; 24: e397-9. doi: 10.1634/theoncologist.2019-0039Parikh RB Galsky MD Gyawali B Riaz F Kaufmann TL Cohen AB et al Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma at the end of life: insights from real-world practice Oncologist 2019 24 e397 9 10.1634/theoncologist.2019-0039Open DOISearch in Google Scholar

24Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 2012; 30: 1715-24. doi: 10.1200/JCO.2012.42.8375Schnipper LE Smith TJ Raghavan D Blayney DW Ganz PA Mulvey TM et al American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology J Clin Oncol 2012 30 1715 24 10.1200/JCO.2012.42.8375Open DOISearch in Google Scholar

25Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A. Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25: iii40-8. doi: 10.1093/annonc/mdu223Bellmunt J Orsola A Leow JJ Wiegel T De Santis M Horwich A Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up Ann Oncol 2014 25 iii40–8 10.1093/annonc/mdu223Open DOISearch in Google Scholar

26Frelaut M, Le Tourneau C, Borcoman E. Hyperprogression under immunotherapy. Int J Mol Sci 2019; 20: 2674. doi: 10.3390/ijms20112674Frelaut M Le Tourneau C Borcoman E Hyperprogression under immunotherapy Int J Mol Sci 2019 20 2674 10.3390/ijms20112674Open DOISearch in Google Scholar

27Khaki AR, Li A, Diamantopoulos LN, Bilen MA, Santos V, Esther J, et al. Impact of performance status on treatment outcomes: a real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer 2020; 126: 1208-16. doi: 10.1002/cncr.32645Khaki AR Li A Diamantopoulos LN Bilen MA Santos V Esther J et al Impact of performance status on treatment outcomes: a real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors Cancer 2020 126 1208 16 10.1002/cncr.32645Open DOISearch in Google Scholar

28Sørensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. an inter-observer variability study. Br J Cancer 1993; 67: 773-5. doi: 10.1038/bjc.1993.140Sørensen JB Klee M Palshof T Hansen HH Performance status assessment in cancer patients an inter-observer variability study. Br J Cancer 1993 67 773 5 10.1038/bjc.1993.140Open DOISearch in Google Scholar

29Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020; 383: 1218-30. doi: 10.1056/nejmoa2002788Powles T Park SH Voog E Caserta C Valderrama BP Gurney H et al Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma N Engl J Med 2020 383 1218 30 10.1056/nejmoa2002788Open DOISearch in Google Scholar

30Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014; 25: 152-65. doi: 10.1016/j.ccr.2014.01.009Choi W Porten S Kim S Willis D Plimack ER Hoffman-Censits J et al Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy Cancer Cell 2014 25 152 65 10.1016/j.ccr.2014.01.009Open DOISearch in Google Scholar

31Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol 2017; 72: 544-54. doi: 10.1016/j.eururo.2017.03.030Seiler R Ashab HAD Erho N van Rhijn BWG Winters B Douglas J et al Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy Eur Urol 2017 72 544 54 10.1016/j.eururo.2017.03.030Open DOISearch in Google Scholar

32Buttigliero C, Tucci M, Vignani F, Scagliotti GV, Di Maio M. Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer. Cancer Treat Rev 2017; 54: 1-9. doi: 10.1016/j.ctrv.2017.01.002Buttigliero C Tucci M Vignani F Scagliotti GV Di Maio M Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer Cancer Treat Rev 2017 54 1 9 10.1016/j.ctrv.2017.01.002Open DOISearch in Google Scholar

33Luo Q, Zhang L, Luo C, Jiang M. Emerging strategies in cancer therapy combining chemotherapy with immunotherapy. Cancer Lett 2019; 454: 191-203. doi: 10.1016/j.canlet.2019.04.017Luo Q Zhang L Luo C Jiang M Emerging strategies in cancer therapy combining chemotherapy with immunotherapy Cancer Lett 2019 454 191 203 10.1016/j.canlet.2019.04.017Open DOISearch in Google Scholar